The total number of shares and votes in Oasmia Pharmaceutical AB (publ) amounts to 85 572 330 as of March 31, 2014. The increase in the number of shares is attributable to a privace placement carried out in March 2014, which comprised 3 800 000 shares.  The share issue was registered in its entirety with the Swedish Companies Registration Office on March 14, 2014.

A list of the company principal shareholders will be available at www.oasmia.com

For more information, please contact:
Mikael Widell, Vice President Communications
Mobile: +46 70 311 99 60
E-mail: mikael.widell@oasmia.com

Notes to editors:

About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops new generations of drugs in the field of human and veterinary oncology. The company’s product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company’s product development is based on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ OMX Stockholm (OASM) and the Frankfurt Stock Exchange (OMAX, ISIN SE0000722365).